, /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85^th Scientific Sessions taking place in Chicago, June 20 – 23, 2025. A total of 29 abstracts will be presented, including trials investigating the efficacy and safety of CagriSema in people with overweight/obesity (REDEFINE 1) and those with overweight/obesity and type 2 diabetes (REDEFINE 2).¹ Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from additional real-world studies in adults with obesity.^2-4

"We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease."

The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's scientific efforts to deliver innovation in cardiometabolic diseases and individualized healthcare solutions.¹

On June 22^nd, Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website.

Full details of Novo Nordisk abstracts to be presented at ADA 2025. These data for medicines containing semaglutide, CagriSema, amycretin, insulin icodec, and IcoSema are investigational:

ADA Scientific Sessions:

Novo Nordisk poster and oral presentations:

Ozempic^® (semaglutide 1 mg)

Rybelsus^® (oral semaglutide)

Wegovy^® (semaglutide 2.4 mg)

Semaglutide 7.2 mg

CagriSema

Amycretin/amylin

Insulin icodec

IcoSema

Digital Health (devices not yet cleared)

General diabetes

• 909-P Prevalence and Factors for Treatment Failure with Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) in U.S. Adults with Type 2 Diabetes (T2D) – Sunday, June 22; 12:30–1:30 pm CDT
• 1870-LB Macrovascular and Microvascular Complications in Medicare Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease From 2006–2021—Incidence Stratified by Sex, Age, and Race/Ethnicity – Sunday, June 22; 12:30–1:30 pm CDT
• 427-P Elevated Body Mass Index at Type 2 Diabetes Diagnosis Is Associated with Increased Risk of Cardiovascular Disease and Kidney Outcomes – Monday, June 23; 12:30–1:30 pm CDT

General obesity

• Health Utilities of People with Obesity in Taiwan: A Nationwide Representative Analysis. Publication Only (63-PUB)

About semaglutide
Semaglutide is a GLP-1 receptor agonist (GLP-1 RA) that is structurally similar to the naturally occurring hormone GLP-1. It works by selectively binding to and activating the GLP-1 receptor. Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases.

Semaglutide is marketed under the brand names Wegovy^® (semaglutide) injection 2.4 mg, Ozempic^® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Rybelsus^® (semaglutide) tablets 7 mg or 14 mg.

About CagriSema
CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg.

About amycretin
Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration.

About obesity 
Obesity is a serious chronic, progressive, and complex disease that requires long-term management.^5-7 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.^5,7 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.^8,9

The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.^10,11 In the U.S., about 40% of adults live with obesity.¹²

About Novo Nordisk 
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.

Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.

Contacts for further information

References       

© 2025 Novo Nordisk                  All rights reserved.                       US25SEMO00776                         June 2025

SOURCE NOVO NORDISK INC.